Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
0.9700
-0.0500 (-4.90%)
At close: Oct 22, 2026, 4:00 PM EDT
0.9774
+0.0074 (0.76%)
After-hours: Oct 22, 2026, 7:38 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year. That makes Cadrenal Therapeutics the 41,816th largest employer in the world and 6,480th in the United States.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,308,760
Market Cap
3.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Enlivex | 34 |
| Dermata Therapeutics | 9 |
| Ernexa Therapeutics | 7 |
| KALA BIO | 6 |
| Eocene | 6 |
| Jupiter Neurosciences | 5 |
| GRI Bio | 4 |
| Addex Therapeutics | 3 |
CVKD News
- 15 days ago - Cadrenal Therapeutics initiates process to evaluate opportunities - TheFly
- 15 days ago - Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics - GlobeNewsWire
- 4 weeks ago - Cadrenal Therapeutics Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference - GlobeNewsWire
- 5 weeks ago - Cadrenal Therapeutics Slides: Investor presentation - Filings
- 7 weeks ago - Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - Cadrenal Therapeutics gets feedback from CAD-1005 Type D Meeting with FDA - TheFly
- 7 weeks ago - Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia - GlobeNewsWire